Descrição
This study was supported by the Minas Gerais State Research Support Foundation (FAPEMIG) protocol number 65/10 and the National Council for Scientific and Technological Development [Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq)] protocol number 310174/2014-7-CNPQ.
Universidade Federal de Minas Gerais. Faculdade de Medicina. Grupo de Pesquisa em Micobacterioses. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Faculdade de Medicina Grupo de Pesquisa em Micobact?rias. Belo Horizonte, MG, Brasil.
Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Instituto Evandro Chagas. Ananindeua, PA, Brasil.
Universidade Federal de Minas Gerais. Faculdade de Medicina Grupo de Pesquisa em Micobact?rias. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Faculdade de Medicina Grupo de Pesquisa em Micobact?rias. Belo Horizonte, MG, Brasil.
Universidade Federal do Rio de Janeiro. Programa Acad?mico de Tuberculose. Rio de Janeiro, RJ, Brasil.
Universidade Federal de Minas Gerais. Faculdade de Farm?cia. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Consultoria e Apoio T?cnico. Belo Horizonte, MG, Brasil.
Introduction: This study aimed to evaluate a new commercial kit, Kit SIRE Nitratase-PlastLabor, for testing the drug susceptibility of clinical Mycobacterium tuberculosis isolates. Methods: The accuracy of the Kit SIRE Nitratase was evaluated by examining the susceptibility (streptomycin, isoniazid, rifampicin, and ethambutol) of 40 M. tuberculosis isolates, using the proportion method with Lowenstein-Jensen medium or the BACTEC MGIT 960 system. Results: The detection accuracy for streptomycin, isoniazid, rifampicin, and ethambutol was 95%, 97.5%, 100%, and 80%, respectively. Conclusions: The exceptional accuracy demonstrated by Kit SIRE Nitratase for isoniazid and rifampicin makes the kit an attractive option for screening M. tuberculosis strain resistance.